Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of Lenzumestrocel (Neuronata-R inj.) in amyotrophic lateral sclerosis
KCT0005954Phase 3Active, not recruiting
- Sponsor
- Corestemchemon
- Start
- Mar 2021
- Modality
- Bone Marrow HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies, Peripheral Blood HSCs → Hematopoietic Stem Cells → Adult Stem Cells → Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in amyotrophic lateral sclerosis (ALS) comparing Lenzumestrocel (Neuronata-R inj.) with Placebo (2 arms). Started Mar 2021; status: active, not recruiting.
02
Drugs
lenzumestrocel
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on KCT0005954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005954.